50 results about "Susceptible individual" patented technology

Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory syncytial virus (RSV). A single recombinant immunogen is capable of protecting infants and similar susceptible individuals against diseases caused by both PIV and RSV.

A method of preventing and/or treating inflammatory bowel disease, particularly ulcerative colitis and Crohn's disease, is disclosed. The method involves administering a 2-methylene-19-nor-vitamin D compound in an amount effective to treat the disease. The administration of a 2-methylene-19-nor-vitamin D compound also prevents the development of or delays the onset of inflammatory bowel disease in susceptible individuals. The preferred compounds are 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol and 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D₃.

The subject invention provides novel amino acid sequences (including a consensus sequence) of the Avian Influenza A virus hemagglutinin protein. These newly constructed genes are designed to provide a broader spectrum of activity across the serotype family thus providing a basis for a vaccine that has broad heterologous disease protection. The novel genes have been further improved by the addition of strategic glycosylation sites into the amino acids sequences that they encode. These genes can also, optionally, be codon optimized for plant expression, inserted into the appropriate vector and cloned into plants for expression. Polypeptides produced by recombinant host cells or transgenic plants can also be used as source of antigen for the formulation of vaccines for the control of influenza in susceptible individuals. Additionally, transgenic plant material may also be used as source of antigen for the formulation of vaccines for the control of influenza in susceptible individuals.

The invention is based on the discovery that certain variants of β-casein may induce Type-1 diabetes in susceptible individuals while other variants do not. The invention consists of the selection of non-diabetogenic milk producing cows and recovering and processing their milk and milk products. Another aspect of the invention is selectively breeding cows which produce the non-diabetogenic milk.

Disclosed are compositions and improved methods for effective treatment of Mycobacterial infections in susceptible animals. Also disclosed are regimens for preventing, reducing, or ameliorating the emergence of symptoms of Mycobacterium tuberculosis infection in susceptible individuals, as well as methods for reducing the spread of tubercular infections in at-risk populations.

The invention discloses an ovarian cancer susceptibility-related molecular marker as well as a detection primer and a kit. The nucleotide sequence of the ovarian cancer susceptibility-related molecular marker is shown by SEQ ID NO:1; and compared with a normal CASR gene, the 719th site has single nucleotide polymorphism: A>G. The primer is shown by SEQ ID NO:2 and SEQ ID NO:3 in the sequence table; and the primer can be used for specifically amplifying the CASR gene, and the length of the amplified fragment is 200-2,700bp. The invention also provides a method for detecting in vitro whether a sample has the single nucleotide polymorphism of the CASR gene. The primer and kit for detecting the ovarian cancer susceptibility-related molecular marker have the advantages of simple, accurate and fast detection and high specificity and are of great importance in effective early diagnosis, early treatment and individual prevention on the high-risk population or susceptible individuals and ovarian cancer patients.

The invention which belongs to the technical field of biological detection relates to a method for detecting MP of sheep and provides the methylation state of CpG islands in an MBL (mannan-binding lectin) gene promoter region related with the MP of sheep and an application thereof. The invention also provides a method for detecting the MP of sheep and concretely relates to the methylation detection of the MBL promoter region and the artificial infection verification. The methylation state detection of the MBL gene promoter region of sheep is carried out through selecting a bisulfite sequencing process, the methylation state and the frequency of each CpG locus in a given region can be accurately detected, three substantially differential CpG methylation loci, CpG3, CpG4 and CpG5, related with the MBL level are found, a case that the MBL level after toxic elimination is lower than the MBL level before the toxic elimination is promoted, and the MBL gene promoter region methylation may be a more substantial characteristic of the MBL level reduction of serum. The method allows the MP infection of sheep and susceptible individuals to be sensitively and accurately detected, and provides complete information and scientific bases for the sheep MBL gene promoter region methylation and the MP infection research of sheep.

Methods, reagents and compositions thereof for predicting RA onset in susceptible individuals, diagnosing RA onset, and/or evaluating efficacy of a therapeutic regimen for treating RA are described herein. Determining the amount of a particular bacterial species comprising SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 (SEQ ID NO: 1+bacteria) serves as a biomarker for the above indications.

A diagnostic test is described using aspergillus flavus fungal cultures, EBV or their combination to induce leukemic cell surface markers in mononuclear cells of former or current leukemia patients. Detection of the leukemic transformation by means known in the art, identified patients who have or had leukemia, or potentially may become leukemic. Unlike aflotoxin, which indiscriminately induces leukemic transformation, the compositions used were specific to leukemia-predisposed patients, but not other cancers or normal controls. The test identifies survivors of ALL and can detect propensity for development of leukemia in susceptible individuals. An ELISA technique using the described fungal products or EBV and combination can detect individuals with history of leukemia and not controls. These findings have implications for the etiology of leukemias and lymphomas. This invention can potentially be used for mass screening, detection of susceptible individuals to leukemia and ultimately their vaccination.

The invention discloses a molecular marker for identifying the susceptibility of an ovarian cancer. The nucleotide sequence of the molecular marker is shown as SEQ ID NO:1, and a single nucleotide polymorphism G)A exists at a bit 1481. A kit for identifying the susceptibility of the ovarian cancer comprises a pair of specific primers of which the sequences are shown as SEQ ID NO:2 and SEQ ID NO:3. A method for identifying whether the single nucleotide polymorphism of a GADD45A gene exists in a sample in vitro comprises the following steps of: (1) amplifying the GADD45A gene of the sample by using specific primers to obtain an amplification product; and (2) sequencing the amplification product and detecting whether a single nucleotide polymorphism, i.e., 1481G)A exists in the amplification product. The method is easy, accurate and rapid for identifying, has high specificity, and has great significances on effective early-diagnosis, early-treatment and personal prevention and treatment on high-risk groups or susceptible individuals and patients suffering from the ovarian cancers.

The invention discloses a molecular marker for detecting susceptibility of ovarian cancer. Nucleotide sequences of the molecular marker are shown in SEQ ID NO.1, and mononucleotide polymorphism, namely T>C is present at 1506th site. A kit for detecting susceptibility of ovarian cancer comprises a pair of specific primers having sequences in SEQ ID NO.2 and SEQ ID NO.3. A method for detecting presence of mononucleotide polymorphism in GADD45A (growth arrest and DNA-damage-inducible protein 45 alpha) gene in a sample in vitro includes: firstly, amplifying the GADD45A gene in the sample by the specific primers to obtain an amplification product; secondly, subjecting the amplification product to sequence determination, and detecting presence of mononucleotide polymorphism, namely 1506T>C, in the amplification product. The method is simple, accurate and fast in detection and high in specificity, and is important to effectively implementing early diagnosis, early treatment and individual prevention and treatment to high risk groups or susceptible individuals and patients with ovarian cancer.

The invention relates to the field of disease diagnosis or screening, discloses application of a mitochondrion MT-CO1 in pyemia screening, and particularly discloses a method for screening individualssusceptible to pyemia on nondiagnostic purpose. The method includes: analyzing whether a basic group at the 6459th position of an individual mitochondrial MT-CO1 gene mutates or not and/or amino acidat the 186th position of a mitochondrial MT-CO1 polypeptide chain mutates or not. The invention further discloses application of a reagent, used for analyzing whether the basic group at the 6459th position of the individual mitochondrial MT-CO1 gene analyzing and/or the amino acid at the 186th position of the mitochondrial MT-CO1 polypeptide chain mutates or not, in preparation of medical instruments for pyemia diagnosis or screening. Based on the mitochondrial MT-CO1 gene or polypeptide chain, early diagnosis or screening of pyemia can be achieved, which is beneficial to infection preventionof susceptible individuals.

The invention discloses an SNP locus related to auxiliary diagnosis of chronic obstructive pulmonary disease susceptibility. The SN locus is rs2227485 and has C/T polymorphism, and compared with a TT+TC genotype, the SN locus has the characteristic that when the genotype is CC, it is judged that an individual is a chronic obstructive pulmonary disease non-susceptible individual. The invention alsodiscloses an application of the SNP locus in preparation of a product for auxiliary diagnosis of chronic obstructive pulmonary disease susceptibility. The SNP locus is beneficial to comprehensive evaluation of COPD occurrence, development and prognosis of Chinese Han people, and has important significance for guiding prevention and screening of COPD high-risk people.

The invention discloses a detecting kit for authenticating cervical cancer susceptibility, and belongs to the technical field of molecular biology and biological medicine. The detecting kit comprisestwo pairs of specificity primers designed based on the hOGG1 gene mononucleotide polymorphism, the 7146th site marked by a molecule with the nucleotide sequence shown in SEQ ID NO.1 has mononucleotidepolymorphism: C)G, and the hOGG1 gene mononucleotide polymorphism rs1052133(C)G) is closely related to the cervical cancer susceptibility. By means of the PCR technology, the mononucleotide polymorphism in a hOGG1 gene can be effectively detected. The method is simple and rapid in detection, high in specificity, low in cost, free of special DNA sequencing devices and convenient to apply and popularize in various levels of clinical hospitals and has great practical significance in screening cervical cancer high-risk people, detecting susceptible individuals and early preventing, early diagnosing and individually controlling the complicated disease (cervical cancer).

Disclosed are compositions and methods for alleviating mucositis, wherein said methods and compositions are directed to the formulation or use of selected nucleoside derivatives, especially ADP-ribose, that conform to the general formula A-B-X and pharmaceutically acceptable salts thereof, wherein “A” is a nucleoside structure selected from adenosine, guanosine, and uridine; “B” is a diphosphate linkage attached to the 5′ carbon of the nucleoside ribose moiety; and “X” is attached to B an is a moiety selected from hydrogen, furanose, or pyranose. Also disclosed are pharmaceuticals and nutritional liquid embodiments thereof, including lozenges, mouthwashes, or other product forms that effectively coat the oral, laryngeal or other mucosal areas. It has been found that these compositions and methods effectively alleviate mucositis in susceptible individuals, especially when administered prior to, during, or after treatments commonly associated with the development of mucositis such as certain chemotherapies, radiation therapies, or combinations thereof.

The present invention refers to the use of AT(n) insertions in promoter elements for controlling the expression levels of coding sequences in plants. The expression levels of the heat shock protein (Gmhsp17.6-L), when compared in resistant and susceptible individuals in the population, demonstrated that the largest expression levels per quantitative PCR were present in the individuals that contained the largest AT insertions in the promoter region. The invention also refers to gene expression cassettes containing promoter regions of the gene with different numbers of AT insertions fused to the GUS protein, for transforming soybean embryos.

The chronic nature of asthma necessitates regular self-monitoring of respiratory function in susceptible individuals, however the available devices for performing the necessary measurements are either inaccurate or expensive and bulky. The present invention provides a small, cheap spirometer for efficient, accurate and convenient measurement of breathing characteristics.

The invention relates to a method and kit for detecting an SNP (Single Nucleotide Polymorphism) site rs10081191 of a susceptible gene region 7q36.3 related to a disease risk of NIHL (Noise Induced Hearing Loss), and application. The method is Sequenom typing. The invention further relates to the kit for detecting the susceptible site and application of the kit. In addition, the SNP site rs10081191of the region 7q36.3 is associated with the disease risk of the NIHL, and the invention discloses the SNP and application thereof. The SNP is located in a human genome region 7q36.3, the 7q36.3 is determined to be a new susceptible gene region of the NIHL, and the SNP can be effectively used for screening susceptible groups of the noise induced hearing loss diseases and determining susceptible individuals of the noise induced hearing loss diseases.

The invention discloses a molecular marker for identifying susceptibility of ovarian cancer. The nucleotide sequence of the molecular marker is presented as SEQ ID NO: 1 and single nucleotide polymorphism (SNP) C) T exists at the 1556 position. A kit for detecting the susceptibility of the ovarian cancer comprises a pair of specific primers provided with sequences of SEQ ID NO: 2 and SEQ ID NO: 3. A method for in vitro detecting whether the SNP of a GADD45A gene exists in a sample includes the steps of amplifying the GADD45A gene of the sample by using the specific primers to obtain amplification products; and performing sequencing on the amplification products to detect whether the SNP 1556C) T exists in the amplification products. According to the molecular marker, the method is simple, accurate and rapid in detection, the specificity is high, and the significance in effective early diagnosis, treatment and individual prevention for high risk groups, susceptible individuals and ovarian cancer patients is provided.